SI20268A - Nesteroidni ligandi za estrogenski receptor - Google Patents

Nesteroidni ligandi za estrogenski receptor Download PDF

Info

Publication number
SI20268A
SI20268A SI9720098A SI9720098A SI20268A SI 20268 A SI20268 A SI 20268A SI 9720098 A SI9720098 A SI 9720098A SI 9720098 A SI9720098 A SI 9720098A SI 20268 A SI20268 A SI 20268A
Authority
SI
Slovenia
Prior art keywords
phenyl
enyl
diphenyl
compound according
preparation
Prior art date
Application number
SI9720098A
Other languages
English (en)
Slovenian (sl)
Inventor
Timothy Mark Willson
Original Assignee
Glaxo Wellcome Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome Inc. filed Critical Glaxo Wellcome Inc.
Publication of SI20268A publication Critical patent/SI20268A/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/28—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by unsaturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/11—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/22—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/35—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/40—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/58—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32—Oximes
    • C07C251/34—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C251/36—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atoms of the oxyimino groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C251/40—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atoms of the oxyimino groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of an unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/34—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring with cyano groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by unsaturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/38—Amides of thiocarboxylic acids
    • C07C327/40—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C327/44—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of an unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/38—Amides of thiocarboxylic acids
    • C07C327/48—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C33/28—Alcohols containing only six-membered aromatic rings as cyclic part with unsaturation outside the aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/45—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/56—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds
    • C07C45/57—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds with oxygen as the only heteroatom
    • C07C45/59—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds with oxygen as the only heteroatom in five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
    • C07C47/548—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings having unsaturation outside the six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/794—Ketones containing a keto group bound to a six-membered aromatic ring having unsaturation outside an aromatic ring
    • C07C49/796—Ketones containing a keto group bound to a six-membered aromatic ring having unsaturation outside an aromatic ring polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C07C57/42—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings having unsaturation outside the rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/46—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid
    • C07C57/48—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid having unsaturation outside the aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/612—Esters of carboxylic acids having a carboxyl group bound to an acyclic carbon atom and having a six-membered aromatic ring in the acid moiety
    • C07C69/618—Esters of carboxylic acids having a carboxyl group bound to an acyclic carbon atom and having a six-membered aromatic ring in the acid moiety having unsaturation outside the six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Steroid Compounds (AREA)
SI9720098A 1994-04-25 1997-08-12 Nesteroidni ligandi za estrogenski receptor SI20268A (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/232,910 US5681835A (en) 1994-04-25 1994-04-25 Non-steroidal ligands for the estrogen receptor
PCT/US1997/013975 WO1999007668A1 (fr) 1994-04-25 1997-08-12 Ligands non steroidien pour le recepteur oestrogenique

Publications (1)

Publication Number Publication Date
SI20268A true SI20268A (sl) 2000-12-31

Family

ID=26792695

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9720098A SI20268A (sl) 1994-04-25 1997-08-12 Nesteroidni ligandi za estrogenski receptor

Country Status (24)

Country Link
US (5) US5681835A (fr)
JP (1) JP4417548B2 (fr)
AT (1) AT500422B1 (fr)
AU (1) AU4147297A (fr)
BR (1) BR9714820A (fr)
CA (1) CA2301189C (fr)
CH (1) CH694250A5 (fr)
CZ (1) CZ301729B6 (fr)
DE (2) DE19782294B4 (fr)
DK (1) DK200000198A (fr)
EE (1) EE200000070A (fr)
FI (1) FI20000294A (fr)
GB (1) GB2344589B (fr)
HK (1) HK1033126A1 (fr)
IL (1) IL134355A0 (fr)
LU (1) LU90525B1 (fr)
LV (1) LV12515B (fr)
NO (1) NO20000657L (fr)
NZ (1) NZ502625A (fr)
RO (1) RO121849B1 (fr)
SE (1) SE0000401L (fr)
SI (1) SI20268A (fr)
UA (1) UA65580C2 (fr)
WO (1) WO1999007668A1 (fr)

Families Citing this family (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
DE69435137D1 (de) 1993-05-13 2008-10-16 Poniard Pharmaceuticals Inc Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind
US5681835A (en) * 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
CA2223595C (fr) 1995-06-07 2008-08-05 Neorx Corporation Prevention et traitement de pathologies cardio-vasculaires au moyen d'analogues de tamoxifene
AR008155A1 (es) * 1996-09-06 1999-12-09 Smithkline Beecham Corp Uso de un compuesto de formula i para preparar un medicamento util para tratar y prevenir la enfermedad cardiovascular post menopausica en mujeres.
ES2186511A1 (es) * 1997-08-12 2003-05-01 Glaxo Wellcome Inc Ligandos no esteroideos para receptor de estrogenos.
EE200000077A (et) * 1997-08-15 2000-12-15 Duke University Östrogeenist sõltuvate haiguste ja häirete vältimise ja ravi meetod
US6222015B1 (en) 1997-09-08 2001-04-24 Merck & Co., Inc. Estrogen receptor
US5990100A (en) * 1998-03-24 1999-11-23 Panda Pharmaceuticals, L.L.C. Composition and method for treatment of psoriasis
HUP0200871A3 (en) 1999-05-04 2004-04-28 Strakan Int Ltd Androgen glycosides and androgenic activity thereof
WO2001023405A2 (fr) 1999-09-30 2001-04-05 Hollis-Eden Pharmaceuticals, Inc. Traitement therapeutique d'affections causees par le recepteur androgene
TW593256B (en) 1999-11-16 2004-06-21 Hormos Medical Oy Ltd Triphenylalkene derivatives and their use as selective estrogen receptor modulators
US6528681B2 (en) * 2000-04-05 2003-03-04 Bristol-Meyers Squibb Pharma Company Halogenated triphenylethylene derivatives as selective estrogen receptor modulators
US6417394B2 (en) * 2000-04-05 2002-07-09 Bristol Myers Squibb Pharma Company Specific salt forms of triphenylethylene derivatives as selective estrogen receptor modulators
WO2002014850A1 (fr) * 2000-08-11 2002-02-21 Ionics, Incorporated Procede et dispositif de controle ionique continu de solutions aqueuses
EP1512413A3 (fr) 2001-01-16 2009-09-23 Glaxo Group Limited Composition pharmaceutique contenant de la 4-amino-quinazoline et un autre agent antinéoplastique, pour le traitement du cancer.
US6599921B2 (en) 2001-02-22 2003-07-29 Nanodesign, Inc. Non-steroidal estrogen receptor ligands
US20030004145A1 (en) * 2001-05-16 2003-01-02 Leonard Thomas W. Treatment of conditions relating to hormone deficiencies by administration of progestins
CZ2004220A3 (cs) * 2001-08-11 2004-06-16 Bristol-Myers Squibb Pharma Company Název neuveden
WO2004069243A1 (fr) 2003-02-04 2004-08-19 Kabushiki Kaisha Yakult Honsha Inhibiteur de proteine de resistance de cancer du sein (bcrp)
US20040248989A1 (en) 2003-06-05 2004-12-09 Risto Santti Method for the treatment or prevention of lower urinary tract symptoms
US7196119B2 (en) 2003-10-21 2007-03-27 The Regents Of The University Of California Development of new selective estrogen receptor modulators
KR101505884B1 (ko) * 2006-05-22 2015-03-25 호르모스 메디칼 리미티드 만성 비세균성 전립선염 치료용 선택적 에스트로겐 수용체 조절제 또는 아로마타아제 저해제
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
WO2008099060A2 (fr) * 2007-02-14 2008-08-21 Hormos Medical Ltd Procédés de préparation de fispémifène à partir d'ospémifène
SI2121553T1 (sl) * 2007-02-14 2012-11-30 Hormos Medical Ltd Postopek za pripravo terapevtsko uporabnih trifenilbutenskih derivatov
US20110129550A1 (en) * 2007-02-16 2011-06-02 Connie Erickson-Miller Cancer treatment method
US20110160130A1 (en) * 2007-02-16 2011-06-30 Connie Erickson-Miller Cancer treatment method
UY30915A1 (es) 2007-02-16 2008-09-02 Smithkline Beecham Corp Método de tratamiento de canceres
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
US20080293683A1 (en) * 2007-05-24 2008-11-27 University Of Kansas Medical Center Hormone Replacement Therapy
CA2709224C (fr) * 2007-10-09 2015-06-23 The Trustees Of The University Of Pennsylvania Agoniste du recepteur de la thrombopoietine (tpora) detruisant les cellules de la leucemie aigue myeloide humaine
NZ591955A (en) 2007-10-16 2011-10-28 Repros Therapeutics Inc Trans-clomiphene for diabetes mellitus type 2
US20090215733A1 (en) * 2008-02-26 2009-08-27 Michael Charles Scally Therapy for the prophylaxis or treatment of adverse body composition changes and/or decreased muscle strength after androgen or gnrh analogue intake
WO2010059658A1 (fr) 2008-11-20 2010-05-27 Glaxosmithkline Llc Composés chimiques
UY32306A (es) 2008-12-09 2010-07-30 Gilead Sciences Inc Derivados de pteridinona y pirimidinodiazepinona y composiciones farmacéuticas que modulan en forma selectiva los receptores tipo toll, métodos y usos
US20110288142A1 (en) 2009-01-30 2011-11-24 Chen Pingyun Y CRYSTALLINE N--5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride
JP5554833B2 (ja) 2009-05-20 2014-07-23 グラクソスミスクライン エルエルシー Ｐｉ３キナーゼ阻害剤としてのチアゾロピリミジノン誘導体
MY162604A (en) 2009-08-17 2017-06-30 Intellikine Llc Heterocyclic compounds and uses thereof
KR101781658B1 (ko) 2009-08-21 2017-10-23 노파르티스 아게 암의 치료 방법
CA2771890A1 (fr) 2009-08-26 2011-03-03 Fabrice Pierre Quinolines condensees utilisees comme modulateurs des proteines kinases
PL2477987T3 (pl) 2009-09-14 2018-06-29 Gilead Sciences, Inc. Modulatory receptorów toll-podobnych
SI2488033T1 (sl) 2009-10-16 2019-10-30 Novartis Ag Kombinacija, ki vsebuje inhibitor MEK in inhibitor B-RAF
US8507507B2 (en) 2009-10-22 2013-08-13 Gilead Sciences, Inc. Modulators of toll-like receptors
US8598156B2 (en) 2010-03-25 2013-12-03 Glaxosmithkline Llc Chemical compounds
EP2580210B1 (fr) 2010-06-10 2017-03-01 Seragon Pharmaceuticals, Inc. Modulateur du récepteur oestrogénique et utilisation de ces derniers
US8853423B2 (en) 2010-06-17 2014-10-07 Seragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
JP6185839B2 (ja) 2010-09-14 2017-08-23 ノバルティス アーゲー Ｂｒａｆ阻害薬とｖｅｇｆ阻害薬との組み合わせ
GB2483736B (en) 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
CA2812608C (fr) 2010-10-06 2020-07-14 Glaxosmithkline Llc Derives de benzimidazole utilises comme inhibiteurs de pi3 kinase
GB201112607D0 (en) 2011-07-22 2011-09-07 Glaxo Group Ltd Novel compounds
TWI505828B (zh) 2010-12-20 2015-11-01 葛蘭素史克智慧財產（第二）有限公司 新穎醫藥組成物
CN103298345B (zh) 2011-01-11 2016-12-14 诺瓦蒂斯公司 组合
CN102617472B (zh) * 2011-01-28 2014-12-03 中国科学院大连化学物理研究所 一种吡唑衍生物的制备方法
US9127000B2 (en) 2011-02-23 2015-09-08 Intellikine, LLC. Heterocyclic compounds and uses thereof
WO2013011153A2 (fr) 2011-07-21 2013-01-24 Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) Méthode pour le pronostic et le traitement d'une métastase dans le cancer du sein
US9187460B2 (en) 2011-12-14 2015-11-17 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
CA2861939A1 (fr) * 2011-12-30 2013-07-04 Centaurus Biopharma Co., Ltd. Nouveaux derives d'arylalcene et utilisation de ceux-ci en tant que modulateurs selectifs de recepteur d'oestrogene
KR20140117644A (ko) 2012-01-31 2014-10-07 스미스클라인 비이참 (코르크) 리미티드 암을 치료하는 방법
EP2819676B1 (fr) 2012-02-29 2018-05-30 Repros Therapeutics Inc. Polythérapie pour le traitement d'une carence en androgène
WO2013142266A1 (fr) 2012-03-20 2013-09-26 Seragon Pharmaceuticals, Inc. Modulateurs de récepteurs d'œstrogènes et leurs utilisations
WO2013143597A1 (fr) 2012-03-29 2013-10-03 Glaxo Group Limited Inhibiteurs d'enzymes de déméthylase
US9321712B2 (en) 2012-10-19 2016-04-26 Fermion Oy Process for the preparation of ospemifene
JP6430390B2 (ja) 2012-11-20 2018-11-28 ジェネンテック， インコーポレイテッド Ｔ７９０ｍを含むｅｇｆｒ変異体の阻害剤としてのアミノピリミジン化合物
EA028246B1 (ru) 2012-11-30 2017-10-31 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Фармацевтическая композиция
JP2016504409A (ja) 2013-01-09 2016-02-12 グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｎｏ．２ Ｌｉｍｉｔｅｄ 組合せ
WO2014108858A1 (fr) 2013-01-10 2014-07-17 Glaxosmithkline Intellectual Property (No.2) Limited Inhibiteurs d'acide gras synthase
GB201311910D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel Compounds
WO2014151147A1 (fr) 2013-03-15 2014-09-25 Intellikine, Llc Combinaison d'inhibiteurs de kinase et ses utilisations
KR20160013049A (ko) 2013-06-03 2016-02-03 노파르티스 아게 항-pd-l1 항체 및 mek 억제제 및/또는 braf 억제제의 조합물
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
RU2016116915A (ru) 2013-10-01 2017-11-13 Новартис Аг Комбинация
BR112016006970A2 (pt) 2013-10-01 2017-08-01 Novartis Ag enzalutamida em combinação com afuresertib para o tratamento de câncer
WO2015056180A1 (fr) 2013-10-15 2015-04-23 Glaxosmithkline Intellectual Property (No.2) Limited Dérivés d'indoline utilisés comme inhibiteurs de perk
KR20160088884A (ko) 2013-12-12 2016-07-26 노파르티스 아게 암의 치료를 위한 트라메티닙, 파니투무맙 및 다브라페닙의 조합물
EP3111222A1 (fr) 2014-02-26 2017-01-04 Glaxosmithkline Intellectual Property (No. 2) Limited Méthodes de traitement de patients atteints de cancer réagissant à l'inhibiteur d'ezh2 gsk126
CN106456642A (zh) 2014-03-12 2017-02-22 诺华股份有限公司 含btk抑制剂与akt抑制剂的组合
LT3122426T (lt) 2014-03-28 2023-03-10 Duke University Krūties vėžio gydymas, naudojant selektyvius estrogenų receptorių moduliatorius
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
WO2016001907A1 (fr) 2014-07-02 2016-01-07 Prendergast Patrick T Mogroside iv et mogroside v utilisables en tant qu'agonistes/stimulateurs/agents de déblocage des récepteurs toll 4 et adjuvant destiné à être utilisé dans un vaccin humain/animal et pour stimuler l'immunité contre des agents pathologiques
TWI806081B (zh) 2014-07-11 2023-06-21 美商基利科學股份有限公司 用於治療HIV之toll樣受體調節劑
PT3194401T (pt) 2014-09-16 2020-12-23 Gilead Sciences Inc Formas sólidas de modulador de recetor tipo toll
WO2016055935A1 (fr) 2014-10-06 2016-04-14 Glaxosmithkline Intellectual Property (No.2) Limited Combinaison d'inhibiteur de déméthylase 1 spécifique à la lysine et d'agoniste de thrombopoïétine
WO2016059602A2 (fr) 2014-10-16 2016-04-21 Glaxo Group Limited Méthodes de traitement du cancer et compositions associées
MA41414A (fr) 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
GB201506871D0 (en) 2015-04-22 2015-06-03 Glaxosmithkline Ip Dev Ltd Novel compounds
EP3331918A1 (fr) 2015-08-04 2018-06-13 GlaxoSmithKline Intellectual Property Development Limited Polythérapies, leurs utilisations et méthodes associées
BR112018002436A2 (pt) 2015-08-04 2018-09-18 Glaxosmithkline Ip Dev Ltd tratamento de combinação de usos de métodos destes
US20180222990A1 (en) 2015-08-04 2018-08-09 Glaxosmithkline Intellectual Property Development Limited Combination Treatments and Uses and Methods Thereof
WO2017021792A1 (fr) 2015-08-06 2017-02-09 Glaxosmithkline Biologicals Sa Agonistes de tlr4, leurs compositions et leur utilisation dans le traitement du cancer
WO2017021912A1 (fr) 2015-08-06 2017-02-09 Glaxosmithkline Intellectual Property Development Limited Modulateurs de tlr combinés avec anticorps anti-ox40
TW201716084A (zh) 2015-08-06 2017-05-16 葛蘭素史克智慧財產發展有限公司 組合物及其用途與治療
WO2017025871A1 (fr) 2015-08-07 2017-02-16 Glaxosmithkline Intellectual Property Development Limited Polythérapie comprenant des anticorps anti-ctla-4
AU2016352592B2 (en) 2015-11-10 2023-04-27 Paracrine Therapeutics Ab Treatment of ER-negative breast cancer with an PDGF-CC inhibitor and an anti estrogen
CA3006934A1 (fr) 2015-12-01 2017-06-08 Glaxosmithkline Intellectual Property Development Limited Combinaison d'anticorps ciblant bcma, pd-1 et ox40 dans les traitements de cancers et utilisations connexes
NZ738202A (en) 2015-12-03 2019-07-26 Glaxosmithkline Ip Dev Ltd Cyclic purine dinucleotides as modulators of sting
WO2017098421A1 (fr) 2015-12-08 2017-06-15 Glaxosmithkline Intellectual Property Development Limited Composés benzothiadiazine
WO2017153952A1 (fr) 2016-03-10 2017-09-14 Glaxosmithkline Intellectual Property Development Limited Dérivés de 5-sulfamoyl-2-hydroxybenzamide
SG11201808708RA (en) 2016-04-07 2018-11-29 Glaxosmithkline Ip Dev Ltd Heterocyclic amides useful as protein modulators
JP6746712B2 (ja) 2016-04-07 2020-08-26 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ タンパク質調節因子として有用な複素環式アミド
JP2019525955A (ja) * 2016-07-12 2019-09-12 アキュター バイオテクノロジー インコーポレイテッド 新規化合物およびその使用
WO2018015879A1 (fr) 2016-07-20 2018-01-25 Glaxosmithkline Intellectual Property Development Limited Dérivés d'isoquinoléine utilisés comme inhibiteurs de perk
EP3494140A1 (fr) 2016-08-04 2019-06-12 GlaxoSmithKline Intellectual Property Development Ltd Polythérapie à base d'anticorps anti-icos et anti-pd-1
US20180072711A1 (en) 2016-09-15 2018-03-15 Arvinas, Inc. Indole derivatives as estrogen receptor degraders
US20190365710A1 (en) 2016-12-01 2019-12-05 Glaxosmithkline Intellectual Property Development Limited Methods of treating cancer
LT3689868T (lt) 2016-12-01 2023-12-27 Arvinas Operations, Inc. Tetrahidronaftaleno ir tetrahidroizochinolino dariniai kaip estrogenų receptorių destruktoriai
CN117551089A (zh) 2017-01-26 2024-02-13 阿尔维纳斯运营股份有限公司 雌激素受体蛋白水解调节剂及相关使用方法
US20190375847A1 (en) 2017-02-15 2019-12-12 Glaxosmithkline Intellectual Property Development Limited Combination treatment for cancer
JP2019529343A (ja) 2017-07-05 2019-10-17 ノバルティス アーゲー 新規な医薬組成物
WO2019021208A1 (fr) 2017-07-27 2019-01-31 Glaxosmithkline Intellectual Property Development Limited Dérivés d'indazole utiles en tant qu'inhibiteurs de perk
UY37866A (es) 2017-09-07 2019-03-29 Glaxosmithkline Ip Dev Ltd Nuevos compuestos derivados de benzoimidazol sustituidos que reducen la proteína myc (c-myc) en las células e inhiben la histona acetiltransferasa de p300/cbp.
WO2019053617A1 (fr) 2017-09-12 2019-03-21 Glaxosmithkline Intellectual Property Development Limited Composés chimiques
CN111417630B (zh) 2017-10-05 2023-06-06 葛兰素史克知识产权开发有限公司 干扰素基因刺激因子(sting)的调节剂
EP3692033A1 (fr) 2017-10-05 2020-08-12 GlaxoSmithKline Intellectual Property Development Limited Modulateurs de stimulateur des gènes (sting) d'interféron utiles dans le traitement du vih
WO2019106605A1 (fr) 2017-12-01 2019-06-06 Board Of Regents, The University Of Texas System Polythérapie pour le traitement du cancer
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
WO2020030570A1 (fr) 2018-08-06 2020-02-13 Glaxosmithkline Intellectual Property Development Limited Combinaisons d'un anticorps ox40 et d'un modulateur de tlr4 et leurs utilisations
WO2020030571A1 (fr) 2018-08-06 2020-02-13 Glaxosmithkline Intellectual Property Development Limited Combinaisons d'un anticorps pd-1 et d'un modulateur de tlr4 et leurs utilisations
EP4342473A3 (fr) 2018-11-30 2024-05-15 GlaxoSmithKline Intellectual Property Development Limited Composés utiles dans la thérapie du vih
WO2020160365A1 (fr) 2019-02-01 2020-08-06 Glaxosmithkline Intellectual Property Development Limited Belantamab mafodotine en combinaison avec du pembrolizumab pour le traitement du cancer
WO2020232375A1 (fr) 2019-05-16 2020-11-19 Silicon Swat, Inc. Dérivés d'acide oxoacridinyle acétique et procédés d'utilisation
JP2022533194A (ja) 2019-05-16 2022-07-21 スティングセラ インコーポレイテッド ベンゾ［ｂ］［１，８］ナフチリジン酢酸誘導体および使用方法
AU2020308053A1 (en) 2019-06-26 2022-01-20 Glaxosmithkline Intellectual Property Development Limited IL1RAP binding proteins
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
WO2021018941A1 (fr) 2019-07-31 2021-02-04 Glaxosmithkline Intellectual Property Development Limited Méthodes de traitement du cancer
JP2023512023A (ja) 2020-01-28 2023-03-23 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 併用療法及びその使用及び方法
WO2023230541A1 (fr) 2022-05-27 2023-11-30 Viiv Healthcare Company Dérivés de pipérazine utiles dans le traitement du vih

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE637389A (fr) * 1962-09-13
US3367856A (en) * 1963-02-07 1968-02-06 Dow Corning Rearrangement of arylsilanes
GB1029221A (en) * 1963-09-02 1966-05-11 Ici Ltd Triarylalkane derivatives
GB1079747A (en) * 1965-07-07 1967-08-16 Ici Ltd Alkene derivatives
US3637856A (en) * 1965-07-12 1972-01-25 Ici Ltd Trans-1-p-(dialkylaminoalkyl) phenyl-1 2-diphenyl-alk-1-enes and salts thereof
GB1128379A (en) * 1966-06-20 1968-09-25 Ici Ltd Novel alkene derivatives, process for the preparation thereof and compositions containing the same
GB1560274A (en) * 1977-02-28 1980-02-06 Ici Ltd Phenylbut 1-ene derivatives having antiostrogenicactivity
EP0002097B1 (fr) * 1977-08-22 1981-08-05 Imperial Chemical Industries Plc Dérivés de triphénylalcène, procédé pour leur préparation et compositions pharmaceutiques les contenant
US4206234A (en) * 1977-08-22 1980-06-03 Imperial Chemical Industries Limited Triphenylbut-1-ene derivatives and pharmaceutical compositions and uses thereof
ATE1418T1 (de) * 1979-05-15 1982-08-15 Imperial Chemical Industries Plc 1-hydrocarbyloxyphenyl-1.2-diphenylalkenderivate, ihre herstellung und sie enthaltende pharmazeutische zusammensetzung.
HU178253B (en) * 1979-08-15 1982-04-28 Gyogyszerkutato Intezet Process for preparing 1,1,2-triphenyl-propane and -propane derivatives
DE3046719C2 (de) * 1980-12-11 1983-02-17 Klinge Pharma GmbH, 8000 München 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel
FI77839C (fi) * 1982-05-27 1989-05-10 Farmos Oy Foerfarande foer framstaellning av nya terapeutiskt effektiva trifenylalkan- och alkenderivat.
CA1229604A (fr) * 1984-02-14 1987-11-24 Lorne J. Brandes Ethers aminoalkyl de phenols utilises comme agents antiproliferatifs contre le cancer
US4729999A (en) * 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
GB8604528D0 (en) * 1986-02-24 1986-04-03 Ici Plc Therapeutic agents
US4859695A (en) * 1986-06-10 1989-08-22 Merck & Co., Inc. Antiestrogen agents having anabolic activity in animals
CA1289570C (fr) * 1986-06-16 1991-09-24 Tetsuji Asao Derives 1,1,2-triaryl-1-alcenes
DE3700005A1 (de) * 1987-01-02 1988-07-14 Elsbett L Kolbenmechanik und kinematik eines axialmotors
DE3736682A1 (de) * 1987-10-29 1989-05-11 Klinge Co Chem Pharm Fab Verfahren zur herstellung von trans-1,1,2-triphenyl-but-1-en-derivaten
US5393785A (en) * 1988-10-31 1995-02-28 Endorecherche, Inc. Therapeutic antiestrogens
US5189212A (en) * 1990-09-07 1993-02-23 University Of Georgia Research Foundation, Inc. Triarylethylene carboxylic acids with estrogenic activity
JPH06504522A (ja) * 1990-10-01 1994-05-26 ボード　オブ　リージェンツ，　ザ　ユニバーシティ　オブ　テキサス　システム 高親和性タモキシフェン誘導体とその使用
WO1992019585A1 (fr) * 1991-04-30 1992-11-12 Asahi Kasei Kogyo Kabushiki Kaisha Derive de triphenylethylene et preparation pharmaceutique contenant celui-ci
US5681835A (en) * 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5965551A (en) * 1996-02-21 1999-10-12 North Carolina State University Method of treating alopecia

Also Published As

Publication number Publication date
US20030073671A1 (en) 2003-04-17
US20010053774A1 (en) 2001-12-20
RO121849B1 (ro) 2008-06-30
UA65580C2 (en) 2004-04-15
GB2344589B (en) 2002-02-06
WO1999007668A1 (fr) 1999-02-18
NZ502625A (en) 2002-04-26
JP2001513525A (ja) 2001-09-04
US5877219A (en) 1999-03-02
NO20000657D0 (no) 2000-02-09
FI20000294A (fi) 2000-02-11
AU4147297A (en) 1999-03-01
JP4417548B2 (ja) 2010-02-17
US5681835A (en) 1997-10-28
GB2344589A (en) 2000-06-14
DE19782294B4 (de) 2007-01-18
DK200000198A (da) 2000-02-09
LV12515A (lv) 2000-07-20
SE0000401L (sv) 2000-04-05
CH694250A5 (fr) 2004-10-15
CZ2000509A3 (cs) 2000-06-14
CA2301189A1 (fr) 1999-02-18
CZ301729B6 (cs) 2010-06-02
LV12515B (en) 2001-07-20
AT500422B1 (de) 2009-03-15
AT500422A1 (de) 2005-12-15
SE0000401D0 (sv) 2000-02-09
GB0005931D0 (en) 2000-05-03
LU90525B1 (de) 2000-02-29
CA2301189C (fr) 2006-05-23
BR9714820A (pt) 2000-08-22
NO20000657L (no) 2000-02-09
EE200000070A (et) 2000-10-16
IL134355A0 (en) 2001-04-30
US6207716B1 (en) 2001-03-27
HK1033126A1 (en) 2001-08-17
DE19782294T1 (de) 2000-08-24

Similar Documents

Publication Publication Date Title
SI20268A (sl) Nesteroidni ligandi za estrogenski receptor
JP3894949B2 (ja) 抗アテローム性動脈硬化症ジアリール化合物
EP0747377B1 (fr) Composés avec des chaínes latérales contenant de l'azote et compositions les contenant
KR20070026841A (ko) 화합물
JP4492848B2 (ja) ２環性化合物
WO2009047343A1 (fr) Dérivés benzocycloheptène comme œstrogènes ayant une activité sélective
WO2003063787A2 (fr) Analogues non steroidiens de 2-methoxyestradiol
CA2178183A1 (fr) Composes et compositions renfermant des chaines laterales azotees non basiques
EP0747380B1 (fr) Composés contenant une pipéridine N-acylée dans la chaine latérale et leurs compositions
KR20060024784A (ko) 성기 종양의 표적 지향성 화학요법
FR2582654A1 (fr) Steroides 11b-substitues utiles notamment dans le traitement des tumeurs hormono-dependantes et procede pour la fabrication
KR100620509B1 (ko) 에스트로겐 수용체에 대한 비스테로이드성 리간드
EP0826670B1 (fr) Dérivés de la naphthalene, intermédiares et utilisation
PL200947B1 (pl) Niesteroidowy ligand receptora estrogenu oraz zastosowanie tego związku i jego analogu
LT4812B (lt) Nesteroidiniai ligandai estrogeno receptoriui
RU2200732C2 (ru) Производные трифенилэтилена, способы лечения и профилактики остеопороза, рака груди и сердечно-сосудистого заболевания
MXPA00001519A (en) Non-steroidal ligands for the estrogen receptor
JP2022510386A (ja) １７－ｈｓｄ１阻害剤としての１６（１７）位でピラゾール環と縮合しているエストラ－１，３，５（１０）－トリエン化合物
WO2009117739A1 (fr) Modulateurs de liaison protéinique de corégulation de récepteur nucléaire
ITBO20090235A1 (it) Composti per il trattamento del tumore alla prostata e procedimenti per la loro sintesi

Legal Events

Date Code Title Description
IF Valid on the event date
KO00 Lapse of patent

Effective date: 20060411